Next gen eTIL / KSQ Therapeutics - LARVOL DELTA

KSQ-004EX: a SOCS1/Regnase-1 dual-edited eTIL therapy demonstrating enhanced anti-tumor activity (SITC 2024) - "Using ExPRESS, a feeder cell-free, next-gen eTIL manufacturing process, TIL were activated and expanded for 11 days whereupon editing of SOCS1 and Regnase-1 was performed by electroporation (EP) of CRISPR/Cas9 ribonucleoprotein (RNP) complexes. Conclusions KSQ-004EX, a SOCS1/Regnase-1 dual CRISPR/Cas9 edited TIL therapy, demonstrated enhanced anti-tumor functionality and in vivo persistence in pre-clinical animal models. These results support the evaluation of KSQ-004EX in a clinical setting in cancer patients with treatment-refractory solid tumors."

Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CCR7 • CD8 • IFNG • IL2 • SOCS1